Market Highlights
Gastrointestinal (GI) drug market involves pharmacological and non-pharmacological treatment. Different types of gastrointestinal disorder includes constipation, diverticular diseases, colon polyps, irritable bowel syndrome, and many more. Many of the GI diseases can be prevented and minimized by maintaining a healthy lifestyle and balanced diet. The factors like increasing prevalence of increasing of various different gastrointestinal disease, increasing elderly population, technological advances are responsible for driving gastrointestinal market. Whereas unavailability of treatment for some of gastro intestinal diseases may be responsible for hampering the market growth.
Americas Market Player for Gastrointestinal Drugs
There are players in global and local gastrointestinal drug market: AbbVie Inc. (US), AstraZeneca (UK), Valeant (US), Abbott Laboratories(US), Allergan Plc (US), Bayer AG (Germany), Janssen Biotech Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Eisai Co., Ltd. (Japan), Valeant Pharmaceuticals (US), Sanofi (France), GlaxoSmithKline Plc. (UK), Boehringer Ingelheim GmbH (Germany). Evoke Pharma (US), Valent Pharmaceuticals(US)
Request For Sample Report: https://www.marketresearchfuture.com/sample_request/583
AstraZeneca has entered into an agreement with gastroenterology specialist Tillotts Pharma for Entocort. Entocort is a gastroenterology medicine for patients with mild to moderate Crohn’s disease and ulcerative colitis. The medicine is now available in across 40 countries, the product sales gained $53 million outside the US in 2014. The agreement shows that Tillotts will pay AstraZeneca $215 million on completion of the transaction to acquire the rights to sell and develop Entocort capsules and formulations outside the US.
Janssen Biotech Inc., the company received FDA approval for the Remicade medicine which is used to treat pediatric ulcerative colitis in 2011. Since then company has a product for pediatric gasrtrointestinal drugs.
GlaxoSmithKline Plc, has a products Eno available in Latin America and Asian market. The product is doing extremely well in these regions. The product is available in various flavor. The product is an antacid. The product is also available in different forms. Company has vast range of products in consumers based and in prescription based products. It hold very strong presence worldwide.
Bayer AG, the company has a wide range of the gastrointestinal products. One of the product Iberogast is herbal product which give relief from multiple problems of gastrointestinal system.
Browse Complete Report: https://www.marketresearchfuture.com/reports/americas-gastrointestinal-drugs-market-583
Segmentation:
The Segmentation for Americas Gastrointestinal Drug market is done on the basis of drug category, route of administration, disease type, and by end users. On the basis of the drug category the market is segmented into Acid Neutralizers, Laxatives & Antidiarrheal, Anti-inflammatory, Antiemetic and others. Further the Acid Neutralizers are sub-segmented into Antacid, H2 antagonists, Proton Pump Inhibitors and others. On the basis of route of administration the segments includes oral, parental and rectal. On the basis of disease type, market is segmented into gastro-esophageal reflux diseases, inflammatory bowel diseases and others. The inflammatory diseases are further segmented into two types Crohn’s diseases and ulcerative disease. The Ulcerative diseases are further sub segmented into ulcerative protitis, proctosigmoiditis, left sided colitis, pancolitis and acute severe ulcerartive colitis. The end user segment includes hospital pharmacies, retail pharmacies and others.
The Business Research Company published its Gastrointestinal Drugs Global Market Report 2020 which provides strategists, marketers and senior management with the critical information they need to assess the global gastrointestinal drugs market.
The report covers the gastrointestinal drugs market’s segments- antacids, antiulcerants, vitamin and minerals, antiobesity, antiemetics and antinauseants, antidiarrheals.View Complete Report: https://www.thebusinessresearchcompany.com/report/gastrointestinal-drugs-global-market-reportGastrointestinal Drugs Global Market Report 2020 is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by region and by country.
It covers all the regions, key developed countries and major emerging markets.
The major regions included in the report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.Drug manufacturing companies are offering tranexamic acid for the treatment of acute gastrointestinal bleeding.
Tranexamic acid is a medication used to treat or prevent excessive blood loss from major trauma or surgery and is now finding applications for gastrointestinal diseases.
The Global Gastrointestinal Cancer Drugs Market Forecast to 2027 published by Reports and Data takes a comprehensive approach towards studying the key trends influencing the growth of this sector.
The research focuses on the changes and progress in the business context due to the recent COVID-19 pandemic.The report evaluates key aspects of the sector to predict the impact of the pandemic on the growth of the market.The report evaluates the latest scenario and is updated with the current alterations in the economy due to COVID-19 pandemic.
The report gives a precise estimation to help readers understand the impact of the pandemic on the concerned market in the forecast years and help combat challenges that may arise in the future.
Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/556Competitive Landscape:Some of the most prominent players include Amgen Limited & Amgen Ireland Limited, Bristol-Myers Squibb Company, Hoffmann-La Roche, Eli Lilly and Company, Celgene Corporation, Pfizer, Sanofi, and Novartis.The report gives an accurate and elaborate evaluation of the market for the forecast period to gain an understanding of the global sector for formulating better investment approaches.
The study further explores and provides in-depth analysis of current market dynamics and recent trends, with special emphasis on various key factors and potential growth opportunities and risks.The report further analyzes the factors and initiatives contributing to the growth of the market.The report focuses on leading regions and their major countries to assess the market growth in the forecast years.
In-depth regional analysis covers: North America (U.S., Canada, Mexico)Europe (U.K., Italy, Germany, France, Rest of EU)AsiaPacific (India, Japan, China, South Korea, Australia, Rest of APAC)Latin America (Chile, Brazil, Argentina, Rest of Latin America)Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/556The competitive landscape of the Gastrointestinal Cancer Drugs market is intense as players are actively engaged in the technological advancements, product developments, product pricing, research innovations, and other growth tactics.
The Business Research Company published its Gastrointestinal Drugs Global Market Report 2020 which provides strategists, marketers and senior management with the critical information they need to assess the global Gastrointestinal Drugs market.
The report provides in-depth analysis of the impact of COVID-19 on the market, along with revised market numbers due to the effects of the coronavirus.The report covers the gastrointestinal drugs market’s segments- 1) By Type: Antacids, Antiulcerants, Vitamin And Minerals, Antiobesity, Antiemetics And Antinauseants, Antidiarrhoeals2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others3) By Route Of Administration: Oral, Parenteral, Others4) By Drug Classification: Branded Drugs, Generic Drugs5) By Mode Of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs.
View Complete Report:https://www.thebusinessresearchcompany.com/report/gastrointestinal-drugs-global-market-report-2020-30-covid-19-implications-and-growthGastrointestinal Drugs Global Market Report 2020 is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies.
The chapter on the impact of COVID-19 gives valuable insights on supply chain disruptions, logistical challenges, and other economic implications of the virus on the market.
The chapter also covers markets which have been positively affected by the pandemic.The global gastrointestinal drugs market is expected to grow from $42.8 billion in 2019 to $48.5 billion in 2020 at a compound annual growth rate (CAGR) of 13.4%.
The growth is mainly due to the impact of COVID-19 on the digestive system.
